ClinicalTrials.gg
Enrolling by invitationNCT07343661BEOMICSUpdated Jan 15, 2026

Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

A Phase 4 interventional study of Mepolizumab 100 MG Injection [Nucala] and Mepolizumab 300 mg in EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma and Eosinophilic Asthma, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Azienda Ospedaliero Universitaria di Cagliari · Phase 4, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Churg-Strauss Syndrome with a site in Italy — 5 open to participants now, 7 under way, 2 of them phase 3. Churg-Strauss Syndrome · Italy.

Started
2025
with 3 others
Phase 4
Only one
of the 13
Registered
9th of 13
by date
Lead sponsor
1 of 13
Azienda Ospedaliero Universitaria di Cagliari

Among the 13 studies in Churg-Strauss Syndrome with a site in Italy, this one is one of 4 that started in 2025, is the only one in phase 4, and was the 9th registered.

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

Browse Churg-Strauss Syndrome studies →

Open to participants now

5 of the 13 studies in Churg-Strauss Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Churg-Strauss Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Aim of the study is to identify potential biomarkers, through a proteomic approach, which could be used to evaluate organ damage and predict the response to mepolizumab in a cohort of patients affected by EGPA. Proteomic analyses will be performed using a proteomic platform, based on a nano-HPLC- couplet to an high resolution ESI-MS device, on three types of biological matrices: blood, saliva and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different time points after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyze the effect of the therapy during treatment, assessing the disease progression on three key aspects: lung function and symptoms control, vasculitis and neuropathy. Plasma analysis will provide an overview of quantitative/qualitative proteomic variations at systemic level after drug administration; however, a less invasive procedure is often sufficient and would improve trial recruitment. On this regard, saliva is a biological fluid well suitable to be used in proteomic investigations for suggestion of potential disease biomarkers and includes various potential advantages compared with blood sample collection such as lower overall cost, lower infection risk, increased patient convenience, acceptability, compliance and uptake. Moreover, the protein composition of the human saliva includes both specific proteins of the oral cavity and proteins common to other tissues and bodily fluids, so saliva prognostic and diagnostic role is particularly interesting. Consequently, the plan is to compare the proteomic results of the non-invasive saliva testing to that of blood examination.

These data may be a further step to untangle the mechanisms of the disease and to characterize treatment's response, in the contest of a phenotype/endotype asthma management.

Read the detailed description

The investigators plan to collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.

untangle the mechanisms of the disease and to characterize response to treatment, in the context of a phenotype/endotype asthma and EGPA management.

03

Conditions studied

  • EGPA - Eosinophilic Granulomatosis With Polyangiitis
  • Severe Asthma
  • Eosinophilic Asthma

Keywords

  • EGPA
  • severe asthma
  • eosinophilic asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : Prior to start any study related activities, participants must be able and willing to provide written informed consent;
  • Participants must have a current clinical diagnosis of asthma or EGPA;
  • Physician decision to initiate treatment with mepolizumab.
  • Patient has to be in treatment with medium-high dose ICS plus an additional controller in the least 6 months before screening and, if on OCS therapy, a stable dosage of prednisone (or equivalent dose of other ) in the 4 weeks before screening will be allowed. The above-indicated treatment has to be maintained by the patient all along the study.
  • Adults aged 18 years or over.

Exclusion criteria

Exclusion Criteria:

  • Asthmatic patients receiving other biological treatment
  • Participation in an interventional clinical trial in which the treatment regimen and/or monitoring is dictated by a protocol during the previous 12 months.
  • Pregnant and breastfeeding woman
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    EGPA with predominant ENT/asthmatic phenotype

    Mepolizumab treatment

    Drug: Mepolizumab 300 mg

  • Experimental
    EGPA with vasculitic phenotype

    immunosuppressive drugs (CYC, AZA, MTX) and/or Mepolizumab

    Drug: Mepolizumab 300 mg

  • Active comparator
    severe eosinophilic asthma

    before and after Mepolizumab treatment

    Drug: Mepolizumab 100 MG Injection [Nucala]

Interventions

  • DrugMepolizumabStudies of MepolizumabMepolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.

  • DrugMepolizumabStudies of MepolizumabMepolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    collect blood, salivary and sputum samples in both EGPA and severe asthmatic patients (as controls) at baseline and at different timepoints after starting treatment with mepolizumab, an anti-IL-5 drug, in order to cluster patients and to analyse the effect of the therapy during treatment and assess the disease progression on three key aspects of the disease: lung function and symptoms control, vasculitis and neuropathy.

06

What researchers measure

Primary outcomes

  1. Saliva, sputum, and plasma proteomic profile of EGPA patients

    Obtain a proteomic profile of EGPA patients and severe asthmatic patients from blood, saliva and sputum. Analyse the samples after starting anti IL - 5 treatment ( mepolizumab ) and evaluate the possible disease modifying effect of the mepoliumab on vas

    Time frame: From the data to the enrollment until the end of the study, up to 52 weeks.

Secondary outcomes

  1. If it is possible to predict the response to treatment by analyzing the proteomic profile of the patients.

    untangle the mechanisms of the disease and to characterize response to treatment, in the context of a phenotype/endotype asthma and EGPA management

    Time frame: From date of randomization until the date of first documented progression, assessed up to 24 months

07

Study locations

1 site
08

References and documents

Publications

  • Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, Cid MC, Gleich GJ, Jayne D, Khoury P, Langford CA, Merkel PA, Moosig F, Specks U, Weller PF, Wechsler ME. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2019 Jun;143(6):2170-2177. doi: 10.1016/j.jaci.2018.11.041. Epub 2018 Dec 19. PubMed 30578883 ↗
  • Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079. PubMed 28514601 ↗
  • Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Bletry O. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010 Jan;125(1):267-70. doi: 10.1016/j.jaci.2009.10.014. No abstract available. PubMed 20109753 ↗
  • Puechal X, Pagnoux C, Baron G, Lifermann F, Geffray L, Quemeneur T, Saraux JL, Wislez M, Cottin V, Ruivard M, Limal N, Aouba A, Bonnotte B, Neel A, Agard C, Cohen P, Terrier B, Le Jeunne C, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group investigators. Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology (Oxford). 2019 Dec 1;58(12):2107-2116. doi: 10.1093/rheumatology/kez139. PubMed 31056661 ↗
  • Samson M, Puechal X, Devilliers H, Ribi C, Cohen P, Stern M, Pagnoux C, Mouthon L, Guillevin L; French Vasculitis Study Group. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013 Jun;43:60-9. doi: 10.1016/j.jaut.2013.03.003. Epub 2013 Apr 13. PubMed 23590801 ↗
  • Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715. No abstract available. PubMed 23045170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — PRIVACY

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Jan 15, 2026
StartActual
Oct 17, 2025
Primary completionEst.
Oct 17, 2026
CompletionEst.
Sep 30, 2028
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07343661
Lead sponsor
Azienda Ospedaliero Universitaria di Cagliari
Responsible party
Giulia Costanzo (sub investigator, Azienda Ospedaliero Universitaria di Cagliari) — Principal investigator
First posted
Jan 15, 2026
Start date
Oct 17, 2025
Primary completion
Oct 17, 2026 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jan 15, 2026

Study contacts

STEFANO DEL GIACCO, MD
principal investigator · AZIENDA OSPEDALIERA UNIVERSITARIA CAGLIARI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mepolizumab

Start the discussion